Apollo Hospitals Enterprise Ltd.
NSE: APOLLOHOSPApollo Hospitals Enterprise Ltd.: A 30-second snapshot
Apollo Hospitals Enterprise trades at ₹8,489.50, up 21.5% over the past 12 months and within 1.6% of its 52-week high, with price above both the 50-DMA (₹8,047) and 200-DMA (₹7,595). The trailing PE of 62.9x is the highest among pharma-drug peers in this group and reflects a significant growth premium, with a forward PE of 39.7x embedding near-term earnings delivery. The company carries a D/E of 85.1 with a rising debt trend, set against 5-year revenue and earnings CAGRs of 18.1% and 35.6% respectively.
P/E
62.9
Forward P/E
39.7
ROE
+21.5%
Debt / Equity
85.15
Profit Margin
+7.7%
Div. Yield
+0.2%
5Y ROE > 15%
2/5
5Y FCF > 0
4/5
Quality
59/100
News
4 headlines · 1 positive · 0 negative
Apollo Hospitals, Federal Bank, GAIL, NBCC: Top stocks to buy - targets, stop loss & more - Business Today
Business Today
Apollo Hospitals Stock - Analyst consensus and strategy backdrop midweek - AD HOC NEWS
AD HOC NEWS
Apollo Hospitals Enterprise Ltd stock (INE438A01022): shares edge higher on NSE India as analyst foc - AD HOC NEWS
AD HOC NEWS
SAIL, Kotak Bank, Dixon Tech, MFSL: 6 stocks to buy for short-term gains — Target prices - Business Today
Business Today
Recent context
- ·News flow over the past month is sparse at 4 items with a neutral aggregate sentiment; coverage has centred on analyst consensus commentary and midweek strategy pieces rather than operational or regulatory developments specific to the company.
- ·The stock is 1.6% from its 52-week high as of the run date, with the nearest identified resistance level at ₹8,624 and key support levels at ₹7,816 and ₹7,561.
- ·30 analysts cover the stock (analyst consensus rating data was not available in numeric form for this run); the company operates in the Pharma sector classification alongside peers that carry meaningfully lower valuation multiples.
Strengths
- +Highest ROE in the 6-stock peer group at 21.5%, ahead of SUNPHARMA (14.7%), DIVISLAB (16.2%), MAXHEALTH (14.3%), Cipla (11.7%), and Dr. Reddys (11.8%).
- +5-year earnings CAGR of 35.6% and revenue CAGR of 18.1% are the strongest growth metrics visible in the peer set, reflecting scale-up of the hospitals and digital health verticals.
- +FCF was positive in 4 of the tracked years, indicating that the capital-intensive expansion model has generated free cash flow in most measured periods.
- +Price is above both the 50-DMA and 200-DMA, with RSI at 63.6 in neutral territory; the 52-week drawdown of 1.6% is minimal, reflecting sustained price momentum over the measurement period.
Weaknesses
- −D/E of 85.1 with a rising debt trend is elevated for a hospital operator; ongoing capex for hospital expansions continues to absorb cash, and ROE has exceeded 15% in only 2 of the tracked years, suggesting the current 21.5% ROE is recent rather than long-established.
- −Trailing PE of 62.9x is 2.2x the peer median of pharma-drug names (Cipla 28.2x, Dr. Reddys 24.7x, SUNPHARMA 38.5x); the forward PE of 39.7x requires earnings delivery well above historical base rates.
- −Quality score of 44 out of 100 ranks 3rd of 6 in the sector peer group; consistency score of 69 and only 2 years of ROE above 15% in the persistence data suggest the quality profile is still maturing.
- −Profit margin of 7.7% is modest in absolute terms for a premium-valued business; small moves in operating costs or payer-mix could have an outsized effect on reported earnings given the current valuation multiple.
Open questions
- ?Does the 35.6% 5-year earnings CAGR reflect a structural shift in hospital economics, or is it disproportionately driven by post-pandemic volume recovery and pricing normalisation that may not persist at the same rate?
- ?At a D/E of 85.1 with a rising trend, how does management plan to balance further hospital expansion capex against debt reduction, and what does the interest coverage trajectory look like as rates remain elevated?
- ?The forward PE of 39.7x implies a meaningful re-rating from the trailing 62.9x — what specific earnings milestones (margin expansion, new unit breakeven timelines) would need to materialise for that compression to occur on schedule?
- ?Apollo operates across hospitals, diagnostics, and digital health — to what extent are the growth and margin profiles of these three verticals diverging, and which segment is driving the most recent ROE improvement?
Peer comparison: Pharma
Ranks 3 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd.You're viewing | 62.9 | +21.5% | 44 |
| Industry avg | across 5 peers | 47.1 | +13.8% | 39 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 38.5 | +14.7% | 59 |
| DIVISLAB | Divi's Laboratories Ltd. | 70.0 | +16.2% | 51 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.2 | +14.3% | 37 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 24.7 | +11.8% | 25 |
| CIPLA | Cipla Ltd. | 28.2 | +11.7% | 24 |
Technical state
Current price
₹8,489.50
SMA 50
₹8,046.89
SMA 200
₹7,595.45
RSI (14)
63.6 (neutral)
From 52w high
-1.6%
1Y return
+21.5%
3M return
+17.1%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumTrailing PE of 62.9x sits well above pharma-drug peers Cipla (28.2x) and Dr. Reddys (24.7x); forward PE of 39.7x narrows the gap but embeds substantial near-term earnings delivery into the current price. Hospital peer MAXHEALTH at 74.2x provides partial sector context.
- mediumDebt-to-equity of 85.1 with a rising debt trend is elevated for a hospital operator. ROE has exceeded 15% in only 2 of the tracked years; FCF was positive in 4 of the available years, but ongoing capital-intensive expansion continues to absorb cash generation.
- mediumQuality score of 44 ranks 3rd of 6 sector peers (SUNPHARMA leads at 59, DIVISLAB at 51). The 5-year earnings CAGR of 35.6% is strong, but multi-year ROE persistence above 15% is not yet confirmed across the full tracked history.
- lowNews sample is sparse at 4 items total; sentiment is driven by one positive item and three neutral items. Concentration in a small sample limits breadth and reliability of the news signal.
Cross-section contradictions
- 5-year earnings CAGR of 35.6% and revenue CAGR of 18.1% are among the stronger growth profiles in the peer group, yet the quality score of 44 and ROE above 15% in only 2 of the tracked years indicate the profitability trajectory is recent and not yet validated as a multi-year structural outcome.
- Price is 1.6% below its 52-week high, above both the 50-DMA (₹8,046.89) and 200-DMA (₹7,595.45), and up 21.5% over 12 months — technical positioning is constructive — yet the trailing PE of 62.9x combined with a rising debt trend and limited ROE history means current pricing embeds sustained execution that the historical quality data does not yet confirm.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 21 Jun 2026 · rotates through NIFTY 500 every ~5 days